24 weeks of interferon-ribavirin therapy should not routinely be given to all hepatitis C patients. [electronic resource]
Producer: 20020314Description: 497-8 p. digitalISSN:- 0002-9270
- Antiviral Agents -- administration & dosage
- Drug Administration Schedule
- Drug Therapy, Combination
- Female
- Follow-Up Studies
- Hepatitis C, Chronic -- diagnosis
- Humans
- Interferon-alpha -- administration & dosage
- Male
- Prospective Studies
- Ribavirin -- administration & dosage
- Risk Assessment
- Sensitivity and Specificity
- Time Factors
- Treatment Outcome
- Viral Load
No physical items for this record
Publication Type: Comment; Letter
There are no comments on this title.
Log in to your account to post a comment.